Evidence map›Paper›PMID 42495710›Full record

Trial reportCancer communications (London, England)2026

Short-Course Radiotherapy-Based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial.

Fengpeng Wu, Xuhua Hu, Baokun Li, Jianfeng Zhang, Guanglin Wang, Haiyan Fan, Guangquan An, Bin Yu, Hongqing Ma, Botian Zhao and 23 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer communications (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Fengpeng WuDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.ORCID 0000-0001-5283-4021
Xuhua HuThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Baokun LiThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Jianfeng ZhangThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Guanglin WangThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Haiyan FanDepartment of Gastroenterology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Guangquan AnThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Bin YuThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Hongqing MaThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Botian ZhaoDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Zhihan LiThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Bo GaoThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Ming LiuDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Xuan WangDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Dan LiuDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Jitao HuThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Hui LiuThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Youqiang LiuThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Feifei WangThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Juan ZhangThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Jun FengThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Xiaoran WangThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Zesong MengThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Zhenya ZhangThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Zheng LiThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Jingyi SunDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Shihao LiuDepartment of General Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050004, P. R. China.
Na WangCancer Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Jing HanDepartment of Medical Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Wenbo NiuThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Chaoxi ZhouThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.
Linlin XiaoDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.ORCID 0000-0003-2001-9131
Guiying WangThe Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P. R. China.ORCID 0000-0001-9601-8210

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyRectal NeoplasmsAdenocarcinomaAdultAgedCapecitabineFemaleHumansMaleMiddle AgedNeoplasm StagingOxaliplatinPathologic Complete ResponseCapecitabineOxaliplatin

Identifiers

PMID42495710
PMCPMC13392285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.